Allogene Therapeutics, Inc. has announced the selection of standard fludarabine and cyclophosphamide $(FC)$ as the lymphodepletion regimen for its ALPHA3 study. This study is evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL). The decision was made in collaboration with the ALPHA3 Data and Safety Monitoring Board and Steering Committee, and following consultation with the U.S. Food and Drug Administration. This marks a strategic shift for Allogene, as the company will not include ALLO-647 in any trials open to enrollment or pipeline programs. Instead, Allogene will focus on advancing next-generation AlloCAR T product candidates utilizing the Dagger® Platform Technology, which aims to minimize or eliminate the need for standard lymphodepletion. This approach is being tested in the ALLO-316 TRAVERSE trial for advanced renal cell carcinoma, and the ALLO-329 RESOLUTION trial for autoimmune diseases. Results of the ALPHA3 study will be presented in the future.